Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Oxurion to Participate in Upcoming Conferences | ||||
By: GlobeNewswire - 01 Jun 2023 | Back to overview list |
|||
Leuven, BELGIUM, Boston, MA, US – June 1, 2023 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that the company will participate in three conferences in June: Knowledge for Growth 2023 Antwerp BIO International 2023 Clinical Trials at the Summit About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com. For further information please contact:
Attachment |
||||
|
||||
Copyright 2023 GlobeNewswire | Back to overview list |